ÔöÇ¿ÃâÒß²ÅÊÇÓ²ÔÀí£¬£¬£¬£¬£¬£¬£¬¸´±ØÌ©¶þ¼ÛÃç½ñÈÕ¿ªÆôÕýʽԤԼ
ÊÂÎñ»ØÊ×
Ø 2022Äê12ÔÂ20ÈÕ£¬£¬£¬£¬£¬£¬£¬¸´±ØÌ©¼°¸´±ØÌ©¶þ¼ÛmRNAÒßÃçÕýʽע²áΪÖйúÏã¸ÛÒ©Æ·/ÖÆÆ·
Ø? 2022Äê12ÔÂ27ÈÕ£¬£¬£¬£¬£¬£¬£¬¹ú¼ÒÒÆÃñÖÎÀí¾ÖÐû²¼£¬£¬£¬£¬£¬£¬£¬ÄÚµØ×¡Ãñ¸°¸Ûǩע½«ÓÚ2023Äê1ÔÂ8ÈÕÓÐÐò»Ö¸´
Ø 2022Äê12ÔÂ27ÈÕ£¬£¬£¬£¬£¬£¬£¬¸´ÐÇ¿µ½¡APP¼°Ð¡³ÌÐòµÚһʱ¼ä¿ªÍ¨ÄÚµØ×¡Ãñ¸°¸Û½ÓÖÖÒâÏòԤԼЧÀÍ
Ø? 2023Äê1ÔÂ4ÈÕ£¬£¬£¬£¬£¬£¬£¬¸´ÐÇ¿µ½¡Â½ÐøÓ뾩¶«¿µ½¡¡¢ÃÀÍÅ¡¢°¢À￵½¡¡¢°Ù¶È¿µ½¡¡¢Î¢Ò½¡¢´ºÓêÒ½ÉúµÈÆ½Ì¨Â½Ðø¿ªÕ¹ÏàÖú£¬£¬£¬£¬£¬£¬£¬ÅäºÏ¿ªÍ¨¸°¸Û½ÓÖÖÒâÏòÔ¤Ô¼
Ø?2023Äê1ÔÂ6ÈÕ£¬£¬£¬£¬£¬£¬£¬¸´ÐÇ¿µ½¡Æ½Ì¨Õýʽ¿ªÆô¸´±ØÌ©¶þ¼ÛÒßÃ縰¸Û½ÓÖÖÔ¤Ô¼¡£¡£¡£¡£¡£¡£¡£¡£Óë´Ëͬʱ£¬£¬£¬£¬£¬£¬£¬¸´ÐÇ¿µ½¡Ò²ÓëÉÏÊö¶àÆ½Ì¨Â½Ðø¿ªÕ¹ÏàÖú¡£¡£¡£¡£¡£¡£¡£¡£ÓÐÐèÇóµÄÓû§¿Éͨ¹ýÉÏÊöÈÎһƽ̨¾ÙÐÐÏßÉÏÔ¤Ô¼£¬£¬£¬£¬£¬£¬£¬Ô¤Ô¼Àֳɺ󼴿ɸ°¸Û×ԷѽÓÖÖ¸´±ØÌ©¶þ¼ÛÒßÃç¡£¡£¡£¡£¡£¡£¡£¡£ÖµµÃ¹Ø×¢µÄÊÇ£¬£¬£¬£¬£¬£¬£¬¸´ÐÇ¿µ½¡×÷Ϊ¸´±ØÌ©ÒßÃçÄÚµØÊ׸öÂÄԼЧÀÍÆ½Ì¨£¬£¬£¬£¬£¬£¬£¬ÒÑÓëÏã¸Û¶à¼ÒÒ½ÁÆ»ú¹¹¼°ÕïËù¸æ¿¢Õ½ÂÔÏàÖú¹ØÏµ£¬£¬£¬£¬£¬£¬£¬½«ÎªÄÚµØ×¡Ãñ¸°¸Û½ÓÖÖ¸´±ØÌ©ÒßÃçÌṩһվʽ±ã½ÝЧÀÍ

Ê×Õ뿪´ò
´Ó¸´±ØÌ©ÒßÃçÔÚÏã¸ÛÕýʽע²á£¬£¬£¬£¬£¬£¬£¬µ½ÄÚµØ×¡Ãñ¿ªÆôÒâÏò±¨Ãû£¬£¬£¬£¬£¬£¬£¬ÔÙµ½ÕýʽԤԼºÍ½ñÈÕÊ×Õ뿪´ò¡£¡£¡£¡£¡£¡£¡£¡£¿£¿£¿£¿£¿ÉÒÔ˵£¬£¬£¬£¬£¬£¬£¬¸´±ØÌ©¶þ¼ÛÒßÃ罫³ÉΪÃñÖÚ·ÀÒßµÄÐÂÑ¡Ôñ£¬£¬£¬£¬£¬£¬£¬Í¬Ê±ÒÀ¸½ÆäÓ¦¶Ô°ÂÃÜ¿ËÈÖ±äÒìÖêµÄÓÐÓ÷À»¤Á¦£¬£¬£¬£¬£¬£¬£¬ÐÅÍпÉÒÔΪÃñÖÚ¿µ½¡±£¼Ý»¤º½¡£¡£¡£¡£¡£¡£¡£¡£

¸´±ØÌ©¶þ¼ÛÒßÃç

2023Äê1ÔÂ6ÈÕ£¬£¬£¬£¬£¬£¬£¬¸´±ØÌ©¶þ¼ÛÒßÃçÏã¸Û×ԷѽÓÖÖÕýʽ¿ª´ò
Ô¤Ô¼Ö¸Òý£º
΢ÐÅËÑË÷¸´ÐÇ¿µ½¡Ð¡³ÌÐò¡ú½øÈëÊ×Ò³µã»÷йÚÒßÃçÔ¤Ô¼¡úµã»÷Ô¤Ô¼±¨Ãû¡úƾ֤ÌáÐÑÌîдÐÅÏ¢¡£¡£¡£¡£¡£¡£¡£¡£
Ô¤Ô¼Àֳɺ󣬣¬£¬£¬£¬£¬£¬´ýÁ½µØÕýʽ»Ö¸´¡°ÍùÀ´¡±£¨¹Ù·½¹«Ê¾1ÔÂ8ÈÕ£©ÄÚµØÇкϽÓÖÖÌõ¼þµÄסÃñ±ã¿ÉÒÀ¸½Ô¤Ô¼ÀÖ³ÉÐÅÏ¢£¬£¬£¬£¬£¬£¬£¬¸°¸Û×ԷѽÓÖÖ¸´±ØÌ©¶þ¼ÛÒßÃçÔöÇ¿Õë¡£¡£¡£¡£¡£¡£¡£¡£
³¤°´Ê¶±ð£¬£¬£¬£¬£¬£¬£¬¡°Â롱ÉÏÔ¤Ô¼
ΪºÎ½ÓÖÖ
Ìý˵ÁËÂ𣿣¿£¿£¿£¿Ð¹ڲ¡¶¾ËüÓÖÓÖÓÖ±äÒìÁË£¬£¬£¬£¬£¬£¬£¬Õâ´ÎÊÇ¡°BBQ£¨Å¶²»£¬£¬£¬£¬£¬£¬£¬Ó¦¸ÃÊÇBQ£©ÓëXXB¡±¡£¡£¡£¡£¡£¡£¡£¡£ÓÈÆä¡°XBB¡±ÌáÉýж¾Íõ£¬£¬£¬£¬£¬£¬£¬¾ßÓÐÏÖÔÚÒÑÖª×îÇ¿µÄÃâÒßÌÓÒÝÄÜÁ¦¡£¡£¡£¡£¡£¡£¡£¡£
?
ÕâÒâζ×Å£¬£¬£¬£¬£¬£¬£¬ÃæÁÙеıäÒì¶¾Ö꣬£¬£¬£¬£¬£¬£¬Ñô¿µÈËÊ¿ÌåÄڵĿ¹ÌåÎÞ·¨ÓÐÓöԿ¹£¬£¬£¬£¬£¬£¬£¬¶þ´ÎѬȾΣº¦½«ÉÏÉý¡£¡£¡£¡£¡£¡£¡£¡£ÍíÄêÈË¡¢ÃâÒß¹¦Ð§µÍÏÂÕߵȸßΣº¦ÈËȺÀ´ËµÍþв±¶Ôö£¬£¬£¬£¬£¬£¬£¬Ñ¬È¾ºóסԺΣº¦¸ü¸ß¡£¡£¡£¡£¡£¡£¡£¡£¶ø¹ØÓÚδÑôÈËȺÀ´Ëµ£¬£¬£¬£¬£¬£¬£¬Ò²½«ÃæÁÙÈ«ÐÂÌôÕ½¡£¡£¡£¡£¡£¡£¡£¡£
?
ÀíÓÉ1.Ñô¿µ²»Êǰٶ¾²»ÇÖ£¬£¬£¬£¬£¬£¬£¬¶þ´ÎѬȾÈÔÐèÖØÊÓ
йڲ¡¶¾Ò»Ö±±äÒ죬£¬£¬£¬£¬£¬£¬Ò»Ö±¡°ÐÞÁ¶¡±£¬£¬£¬£¬£¬£¬£¬ÌÓÒÝÏÖÓÐÒßÃç»òйÚѬȾ¼¤»îµÄ»úÌåÃâÒßÁ¦¡£¡£¡£¡£¡£¡£¡£¡£ºÃ±È£¬£¬£¬£¬£¬£¬£¬ÏÖÔÚº£ÄÚÊ¢ÐÐÖêÖ÷ÒªÊÇBA.5Æ×ϵ£¬£¬£¬£¬£¬£¬£¬¿ÉÊÇÎ÷Å·¹ú¼Ò£¬£¬£¬£¬£¬£¬£¬Ê¢ÐÐÖêÒѾÖð½¥±»ÃâÒßÌÓÒÝÄÜÁ¦¸üÇ¿µÄBQ.1.1ºÍXBB.1.5È¡´ú¡£¡£¡£¡£¡£¡£¡£¡£
ÔÙÕߣ¬£¬£¬£¬£¬£¬£¬ÆñÂÛÊÇ×ÔȻѬȾÕվɽÓÖÖÒßÃ磬£¬£¬£¬£¬£¬£¬ÉíÌåËù»ñµÃ¶Ô¿¹²¡¶¾µÄÃâÒßÁ¦²¢·Ç³¤ÆÚÓÐÁ¦£¬£¬£¬£¬£¬£¬£¬¶øÊÇËæ×Åʱ¼äÍÆÒÆ£¬£¬£¬£¬£¬£¬£¬²»¿É×èÖ¹µØ·ºÆð±£»£»£»£»£»¤Á¦½µµÍµÄÇéÐΡ£¡£¡£¡£¡£¡£¡£¡£
?
ÓÈÆä¹ØÓÚ¸ßΣº¦ÈËȺÀ´Ëµ£¨ÈçÍíÄêÈË£¬£¬£¬£¬£¬£¬£¬»ù´¡¼²²¡µÄÈËȺ£¬£¬£¬£¬£¬£¬£¬·ÊÅÖÕߵȸßΣº¦ÒòËØÈËȺ£©£¬£¬£¬£¬£¬£¬£¬¸üÈÝÒ×¶à´ÎѬȾ£¬£¬£¬£¬£¬£¬£¬×¡Ôº¡¢·ºÆðÖØÖ¢£¬£¬£¬£¬£¬£¬£¬ÇÒºóÒÅÖ¢£¨Èç·Î²¡¡¢ÐÄѪ¹Ü²¡¡¢ÑªÒº²¡¡¢ÌÇÄò²¡¡¢Î¸³¦²¡¡¢Éö²¡¡¢¾«Éñ¼²²¡¡¢¼¡Èâ¹Ç÷À²¡ºÍÉñ¾¼²²¡µÈ£©Î£º¦¸ü¸ß¡£¡£¡£¡£¡£¡£¡£¡£
?
Òò´Ë£¬£¬£¬£¬£¬£¬£¬¡°Ñô¿µ¡±Ö®ºó²»¿ÉµôÒÔÇáÐÄ£¬£¬£¬£¬£¬£¬£¬¶ø¸ßΣº¦ÈËȺ¸üÓ¦×Ô¶¯³ö»÷ÖÆ¶©ÊʺÏ×Ô¼ºµÄ±£»£»£»£»£»¤Õ½ÂÔ£¬£¬£¬£¬£¬£¬£¬Ô¤·ÀÖØ¸´Ñ¬È¾¡£¡£¡£¡£¡£¡£¡£¡£ÖÁÓÚÉÐδѬȾµÄÈËȺ£¬£¬£¬£¬£¬£¬£¬¸üÓ¦ÔöÇ¿ÃâÒߣ¬£¬£¬£¬£¬£¬£¬ÊØ×¡À´Ö®²»Ò׵ġ°Î´Ñô¡±¡£¡£¡£¡£¡£¡£¡£¡£
?
ÀíÓÉ2.Ñô¿µºó½ÓÖÖÒßÃ磬£¬£¬£¬£¬£¬£¬ÓÐÓýµµÍѬȾΣº¦
ÊÂʵʤÓÚÐ۱磬£¬£¬£¬£¬£¬£¬À´¿´¼¸ÏîÑо¿Ð§¹û£º
ÆäÒ»£¬£¬£¬£¬£¬£¬£¬ÒÔÉ«ÁÐÒ»Ïî½ü29Íòйڿµ¸´ÕßÑо¿Ö¤Êµ£¬£¬£¬£¬£¬£¬£¬Ð¹ڿµ¸´»¼Õß½ÓÖÖ¸´±ØÌ©mRNAÒßÃçÄÜÏÔÖø½µµÍÔÙѬȾ±¬·¢ÂÊ¡£¡£¡£¡£¡£¡£¡£¡£ÆäÖУ¬£¬£¬£¬£¬£¬£¬16~64ËêÄêËê×éÒßÃç±£»£»£»£»£»¤ÂÊΪ82%£¬£¬£¬£¬£¬£¬£¬65ËêÒÔÉÏÈËȺΪ60%¡£¡£¡£¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬£¬½ÓÖÖÁ½¼Á¸´±ØÌ©mRNAÒßÃ磬£¬£¬£¬£¬£¬£¬¿Éʹ¼±ÐÔйںóÒÅÖ¢µÄ³£¼ûÖ¢×´£¨Æ£ÀÍ£¬£¬£¬£¬£¬£¬£¬Í·Í´£¬£¬£¬£¬£¬£¬£¬ËÄÖ«·¦Á¦£¬£¬£¬£¬£¬£¬£¬¼¡ÈâÒ»Á¬ÌÛÍ´µÈ£©Î£º¦Ï½µ50%ÒÔÉÏ¡£¡£¡£¡£¡£¡£¡£¡£Óɴ˿ɼû£¬£¬£¬£¬£¬£¬£¬Ñô¿µºó½ÓÖÖÒßÃç¿ÉÒÔÓÐÓýµµÍÔÙѬȾÒÔ¼°½µµÍйںóÒÅÖ¢±¬·¢ÂÊ¡£¡£¡£¡£¡£¡£¡£¡£
?
Æä¶þ£¬£¬£¬£¬£¬£¬£¬2022Äê12ÔÂ16ÈÕ£¬£¬£¬£¬£¬£¬£¬ÃÀ¹ú¼²¿ØÖÐÐĽÒÏþÒªº¦Êý¾Ý£¬£¬£¬£¬£¬£¬£¬Ê״θø³öÁËmRNA¶þ¼ÛÒßÃçÔöÇ¿½ÓÖÖÓëδ½ÓÖÖÒßÃç×éÏà±È£¬£¬£¬£¬£¬£¬£¬65Ëê¼°ÒÔÉÏ£¬£¬£¬£¬£¬£¬£¬70%ÒÔÉÏ»¼ÓÐÒ»ÖÖ¼°ÒÔÉÏ»ù´¡¼²²¡µÄÈËȺÖÐÔ¤·ÀйÚסԺµÄÒßÃçÓÐÓÃÐÔΪ84%¡£¡£¡£¡£¡£¡£¡£¡£Óɴ˿ɼû£¬£¬£¬£¬£¬£¬£¬ÍíÄêÈËȺ¼°Óлù´¡¼²²¡ÕßÔöÇ¿½ÓÖÖ¿ÉÒÔ»ñµÃ¸üΪÓÐÓõı£»£»£»£»£»¤£¬£¬£¬£¬£¬£¬£¬½µµÍÔÙѬȾ¼°×¡ÔºÎ£º¦¡£¡£¡£¡£¡£¡£¡£¡£
?
ÆäÈý£¬£¬£¬£¬£¬£¬£¬2022Äê12ÔÂ21ÈÕ£¬£¬£¬£¬£¬£¬£¬ÐÂÓ¢¸ñÀ¼Ò½Ñ§ÔÓÖ¾£¨NEJM£©½ÒÏþÁËÃÀ¹úEmory´óѧµÄÖ÷ÒªÑо¿ÂÛÎÄ£¬£¬£¬£¬£¬£¬£¬Ð§¹ûÏÔʾ£¬£¬£¬£¬£¬£¬£¬Íê³Éµ¥¼ÛÒßÃç½ÓÖֺ󣬣¬£¬£¬£¬£¬£¬ÔöÇ¿½ÓÖÖmRNA¶þ¼ÛÒßÃ磬£¬£¬£¬£¬£¬£¬¹ØÓÚÏÖÔÚÃâÒßÌÓÒÝ×îÑÏÖØµÄÖ÷Òª±äÒìÖêBQ.1.1ºÍXBBÈÔ¾ßÓнϸߵĿ¹Ìåˮƽ¡£¡£¡£¡£¡£¡£¡£¡£Óɴ˿ɼû£¬£¬£¬£¬£¬£¬£¬ÔöÇ¿½ÓÖÖmRNA¶þ¼ÛÒßÃ磬£¬£¬£¬£¬£¬£¬¹ØÓÚÔ¤·ÀÊ¢ÐеıäÒì¶¾ÖêͬÑù¾ßÓб£»£»£»£»£»¤Á¦¡£¡£¡£¡£¡£¡£¡£¡£
?
ÀíÓÉ3£ºÈ¨ÍþÍÆ¼ö»ìÕëÔöÇ¿£¬£¬£¬£¬£¬£¬£¬¼Ó±¶ÌáÉý±£»£»£»£»£»¤Ð§Á¦
»ùÓÚÎÒ¹úÏÖÕæÏàÐÎÀ´Ëµ£¬£¬£¬£¬£¬£¬£¬´ó´ó¶¼ÈËÒѽÓÖÖ¹ýÒ»ÖÁÈý¼Á²»µÈµÄйÚÃð»îÒßÃ磬£¬£¬£¬£¬£¬£¬¶øÔÚ´Ë»ù´¡ÉÏ¡°ÒìÔ´ÔöÇ¿£¬£¬£¬£¬£¬£¬£¬¼´»ìÕ롱¿ÉÒÔ»ñµÃ¸ü¸ßµÄ±£»£»£»£»£»¤Ð§Á¦£º
l ?²î±ðÒßÃçÖ®¼ä¿ÉÒÔÓÅÊÆ»¥²¹£¬£¬£¬£¬£¬£¬£¬¶Ô¿¹¶¾ÖêµÄ±äÒ죻£»£»£»£»
l ?СÎÒ˽¼ÒÌåÖÊ·×ÆçÑù£¬£¬£¬£¬£¬£¬£¬¿ÉÄܶÔijһÀàÒßÃçµÄ¸±×÷ÓöàһЩ£¬£¬£¬£¬£¬£¬£¬»»Ò»¸öÒßÃ磬£¬£¬£¬£¬£¬£¬·´µ¹¿ÉÒÔ¹æ±Ü²»Á¼·´Ó¦¡£¡£¡£¡£¡£¡£¡£¡£
?
ÕýÈçÖÓÄÏɽԺʿÔÚÖлªÒ½Ñ§»áºôÎü²¡Ñ§Äê»áÉϵı¨¸æÖÐÌáµ½£¬£¬£¬£¬£¬£¬£¬ÒìÔ´ÔöÇ¿ÃâÒߣ¬£¬£¬£¬£¬£¬£¬ÈçÔÚÁ½¼ÁÃð»îÒßÃçµÄ»ù´¡ÉÏ£¬£¬£¬£¬£¬£¬£¬¼ÓÓÃmRNAÒßÃçµÈÒìÖÖÒßÃ磬£¬£¬£¬£¬£¬£¬Ô¤·ÀЧ¹û»áÏÔ×ÅÌá¸ß£¬£¬£¬£¬£¬£¬£¬²¢ÇÒÐèÖØµãÔöÇ¿ÍíÄêÈ˼°Å³ÈõÈËȺµÄÃâÒß½ÓÖÖ¡£¡£¡£¡£¡£¡£¡£¡£
Êý¾ÝÅú×¢£¬£¬£¬£¬£¬£¬£¬¸´±ØÌ©mRNA¶þ¼ÛйÚÒßÃç×÷ΪÔöÇ¿¼Á½ÓÖֺ󣬣¬£¬£¬£¬£¬£¬Õë¶Ô°ÂÃÜ¿ËÈÖ BA.1¡¢BA.2ºÍBA.4/BA.5±äÒìÖêÒÔ¼°ÔʼÖêµÈ²¡¶¾¾ù¿É±¬·¢Ç¿ÁÒµÄÖкͿ¹Ìå·´Ó¦£¬£¬£¬£¬£¬£¬£¬ÓëÔʼÖêÒßÃçÏà±È£¬£¬£¬£¬£¬£¬£¬¾ßÓиüºÃµÄÃâÒßÔÐԺ͹ãÆ×ÐÔ£¬£¬£¬£¬£¬£¬£¬ÄÜÁýÕÖ¸ü¶àµÄ°ÂÃÜ¿ËÈÖ±äÒìÖ꣬£¬£¬£¬£¬£¬£¬ÌáÉý±£»£»£»£»£»¤Á¦¡£¡£¡£¡£¡£¡£¡£¡£

×îºó£¬£¬£¬£¬£¬£¬£¬¹ØÓÚ¸÷ÈËÊ®·Ö¹Ø×¢µÄÎÊÌ⡪¡ª¸°¸Û´òÒßÃç²î±ðÈËȺÔõô´ò£¿£¿£¿£¿£¿ÏêÇé°Ý¼ûÏÂͼָÒý£º
²Î¿¼ÎÄÏ×£º
1.Davis-Gardner ME, et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N Engl J Med. 2022 Dec 21.
2.https://www.statista.com/statistics/1254250/share-of-older-us-adults-fully-or-partially-vaccinated-against-covid/
3.Hammerman, Ariel; et al. (2022): Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19. In The New England journal of medicine 386 (13), pp. 1221¨C1229.
4.Paul Kuodi, Yanay Gorelik, Hiba Zayyad et al. Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel. NPJ Vaccines . 2022 Aug 26;7(1):101.
5.WHO. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1 Accessed 29 Dec 2022.
6.US CDC. https://www.cdc.gov/vaccines/covid-19/downloads/summary-interim-clinical-considerations.pdf Accessed 29 Dec 2022.
7.UK JCVI.?https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1110045/COVID-19-vaccine-information-for-healthcare-practitioners-version-5.pdf Accessed 29 Dec 2022.
8.AGATI. https://www.health.gov.au/our-work/covid-19-vaccines/getting-your-vaccination/vaccination-after-covid-19-infection Accessed 29 Dec 2022.
9.Canada NACI. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#t5 Accessed 29 Dec 2022.
10Israeli MoH. https://corona.health.gov.il/en/vaccine-for-covid/#:~:text=All%20Israeli%20citizens%20aged%205,for%20vaccination%20against%20COVID%2D19.&text=Even%20those%20who%20recovered%20from,result%20on%20a%20serologic%20test Accessed 29 Dec 2022.
11.South Africa DoH. https://www.knowledgehub.org.za/elibrary/interval-between-sars-cov-2-infections-and-covid-19-vaccination Accessed 29 Dec 2022.





